Compare ALT & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALT | ETON |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.5M | 683.7M |
| IPO Year | 2005 | 2018 |
| Metric | ALT | ETON |
|---|---|---|
| Price | $3.51 | $24.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $17.67 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 2.5M | 471.3K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $41,000.00 | ★ $79,950,000.00 |
| Revenue This Year | N/A | $40.90 |
| Revenue Next Year | N/A | $47.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 105.00 | 104.94 |
| 52 Week Low | $2.87 | $13.09 |
| 52 Week High | $7.73 | $27.29 |
| Indicator | ALT | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 51.91 | 54.47 |
| Support Level | $3.40 | $16.38 |
| Resistance Level | $3.54 | N/A |
| Average True Range (ATR) | 0.17 | 1.23 |
| MACD | 0.07 | -0.15 |
| Stochastic Oscillator | 96.32 | 40.16 |
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.